Search clinical trials for: Cilastatin

Total 48 results

Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Spero Therapeutics
GlaxoSmithKline

Recruiting

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO)

Urinary Tract Infection | Acute Pyelonephritis

Moldova, Republic of, Georgia, United States, Serbia, Bulgaria, Romania, South Africa
Meiji Seika Pharma Co., Ltd.

Recruiting

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis (Integral-1)

Acute Pyelonephritis | Complicated Urinary Tract Infection

Estonia
Hartford Hospital
Merck Sharp & Dohme LLC; University of Texas Southwestern Medical Center; University... and other collaborators

Recruiting

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

Pneumonia, Bacterial | Cystic Fibrosis

United States
Evopoint Biosciences Inc.

Recruiting

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Recarbrio in Adults With HABP /VABP (REITAB-2)

Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

United States, Spain, France, Israel
Evopoint Biosciences Inc.

Not yet recruiting

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

Complicated Urinary Tract Infection Including Acute Pyelonephritis

United States
Merck Sharp & Dohme LLC

Recruiting

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Suspected or Documented Gram-negative Bacterial Infection

United States, Bulgaria, Colombia, France, Greece, Hungary, Israel, Mexico, Philippines, Poland, Russian Federation, South Africa, Spain, Turkey, Ukraine, Estonia, Chile, Norway
Beijing Children's Hospital
Hopital Universitaire Robert-Debre; Shandong University; Rennes University Hospital

Recruiting

Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

Tuberculosis

China
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
Joseph L. Kuti, PharmD
Merck Sharp & Dohme LLC

Completed

Imipenem/Cilastatin/Relebactam PK in ECMO

Sepsis

United States
Merck Sharp & Dohme LLC

Completed

Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)

Hospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia

Mexico, Brazil, China, France, Philippines, Romania, Russian Federation, Ukraine
Evopoint Biosciences Inc.

Completed

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Bacterial Infections

United States
Evopoint Biosciences Inc.

Completed

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

Bacterial Infections

United States
Evopoint Biosciences Inc.

Completed

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Bacterial Infections

United States
Evopoint Biosciences Inc.

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

Bacterial Infections

United States
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC

Withdrawn

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Gram-Negative Bacterial Infections | Antibiotic Resistant Infection | Carbapenem-Resistant Enterobacteriaceae Infection | KPC

United States
University of Illinois at Chicago
Merck Sharp & Dohme LLC

Enrolling by invitation

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Obesity | Critical Illness

United States
Julio Ramirez
University of Louisville

Terminated

Patients Response to Early Switch To Oral:Osteomyelitis Study (PRESTO:Osteo)

Osteomyelitis

United States
Ain Shams University

Unknown

Efficacy and Safety of Colistin Based Antibiotic Therapy

Bacterial Infections | Septicemia

Egypt
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

Complicated Intra-abdominal Infection | Complicated Urinary Tract Infection

Japan
Merck Sharp & Dohme LLC

Completed

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Infectious Disease
Prince of Songkla University

Unknown

PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients

Critical Illness | Bacterial Infections

Thailand
Merck Sharp & Dohme LLC

Completed

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (RESTORE-IMI 2)

Bacterial Pneumonia
Entasis Therapeutics

Completed

Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections

Acute Pyelonephritis | Complicated Urinary Tract Infection

Bulgaria
Shionogi

Completed

A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections (APEKS-cUTI)

Urinary Tract Infections
Amsterdam UMC, location VUmc
ZonMw: The Netherlands Organisation for Health Research and Development; Fo...

Completed

Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO (SHORT)

Febrile Neutropenia | Hematological Malignancy

Netherlands
Merck Sharp & Dohme LLC

Completed

Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

Intra-abdominal Infections
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

Urinary Tract Infections | Pyelonephritis
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia

Pneumonia | Bacterial Infections | Pneumonia, Bacterial | Abdominal Abscess | Pneumonia, Ventilator-Associated
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) (RESTORE-IMI 1)

Bacterial Infections
Spherium Biomed
Hospital Universitario La Paz

Completed

Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers.

Dose Finding Study

Spain
Pfizer

Completed

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

Complicated Urinary Tract Infection

United States, Lebanon, Jordan
Pfizer

Completed

A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

Intra-abdominal Infection

China
GlaxoSmithKline

Terminated

GSK2251052 in Complicated Urinary Tract Infection

Infections, Urinary Tract

France, United States, Russian Federation, Spain, Greece, Canada
Pfizer

Completed

Complicated Skin and Skin Structure Infections

Abscess | Cellulitis | Skin Infection
Central Hospital, Nancy, France

Terminated

Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli (COLIFOX)

Urinary Tract Infections

France
University Hospital Rijeka
University of Rijeka

Completed

Imipenem Prophylaxis in Patients With Acute Pancreatitis (IMPROWE)

Acute Pancreatitis

Croatia
Entasis Therapeutics

Completed

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

Acinetobacter Baumannii Infection

Australia
Merck Sharp & Dohme LLC

Completed

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Pneumonia | Infection
Geron Corporation

Completed

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (ET/PV)

Polycythemia Vera | Essential Thrombocythemia

United States, Germany, Switzerland
Southeast University, China
Merck Sharp & Dohme LLC

Unknown

Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin (PROTDOI)

Sepsis

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

Gram-Positive Bacterial Infections | Cross Infection
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

Ventilator-Associated Pneumonia

United States, Australia, Germany, France, Spain, Argentina, Mexico, Portugal, India, Romania, Turkey, Ukraine, Canada, Belgium, Brazil, Philippines, Russian Federation, Hungary, Israel, Thailand, Guatemala
Pfizer

Terminated

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

Pneumonia, Bacterial

Canada, United States, Argentina, Australia, Brazil, Chile, Colombia, Croatia, France, Hungary, Korea, Republic of, Latvia, Russian Federation, Taiwan
Johnson & Johnson Pharmaceutical Research & Development...
PriCara, Unit of Ortho-McNeil, Inc.

Completed

A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization

Nosocomial Pneumonia
Ruijin Hospital
Pfizer

Unknown

Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia

Pneumonia, Ventilator-Associated | Methicillin-resistant Staphylococcus Aureus
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections

Abdominal Abscess

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

Bacterial Pneumonia

United States

3

Subscribe